Management Decision Bayer Appoints New Head of Pharma Business Development & Licensing/Open Innovation

Related Vendors

Glatt Ingenieurtechnik GmbH

Maag Pump Systems AG

Italvacuum, Srl

Bayer AG

Juergen Eckhardt has been appointed by Bayer as the new Head of Business Development & Licensing / Open Innovation of its pharma division. He will take charge from September 1, 2023.

Berlin/Germany – Bayer has recently appointed Juergen Eckhardt MD, MBA as the new Head of Business Development & Licensing / Open Innovation (BDL/OI) of its Pharmaceuticals Division effective September 1, 2023. He will join the Pharmaceuticals Executive Committee and report to Stefan Oelrich, Member of the Board of Management, Bayer, and President of the company's Pharmaceuticals Division. At the same time, Eckhardt will continue to lead Leaps by Bayer, the company’s impact investment arm and in that role continue to report to Bill Anderson, Chairman of the Board of Management of Bayer.

“Juergen’s expertise of more than 25 years in the healthcare industry as a physician, strategy consultant and venture capital investor in healthcare, biotech, and agriculture will be key to lead our external growth strategy,” said Stefan Oelrich, Member of the Board of Management, Bayer, and President of the company's Pharmaceuticals Division. “At the same time, I like to express my sincere gratitude to Friedemann Janus for stepping in as acting head of the BDL/OI organization in the past months.”

Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer, focusing on investments in breakthrough technologies in health and agriculture. Since then, Leaps by Bayer invested more than 1.7 billion dollars in more than 55 companies, several of which have been acquired by Bayer to strengthen Bayer’s technology portfolio and pipeline. Eckhardt began his career as a physician at the University Hospital of Basel, Switzerland and was a management consultant with McKinsey & Co. as well as a Venture Capital investor prior to joining Bayer. He has been a board member of numerous biotech companies and has led many partnering transactions throughout his career. Juergen received his MD from the University of Basel and his MBA from the “Institut Européen d’Administration des Affaires” (Insead) in Fontainebleau, France.

(ID:49671690)